FDA Approves Daratumumab Plus Carfilzomib and Dexamethasone for Relapsed or Refractory Multiple Myeloma.
Indomethacin enhances anti-tumor efficacy of a MUC1 peptide vaccine against breast cancer in MUC1 transgenic mice.
FDA Pipeline: Priority Reviews for Immunotherapy Dose Regimen, Small Cell Lung Cancer; Fast Track Designations in Brain Cancer and Leukemia.
Olaparib and durvalumab in patients with germline BRCA-mutated metastatic breast cancer (MEDIOLA): an open-label, multicentre, phase 1/2, basket study.
Bevacizumab Plus mFOLFOX6 Versus mFOLFOX6 Alone as First-Line Treatment for RAS Mutant Unresectable Colorectal Liver-Limited Metastases: The BECOME Randomized Controlled Trial.
Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a multicentre, randomised, placebo-controlled phase 3 trial.
Pembrolizumab for Early
Triple-Negative Breast Cancer.
Pazopanib for treatment of advanced extraskeletal myxoid chondrosarcoma: a multicentre, single-arm, phase 2 trial.
Personalized RNA-Based Vaccine/Atezolizumab Combination Produced Immune Response in Most Patients With Advanced Tumors.
Berzosertib plus gemcitabine versus gemcitabine alone in platinum-resistant high-grade serous ovarian cancer: a multicentre, open-label, randomised, phase 2 trial.
FDA Approves Combination of Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf for HER2-Positive Breast Cancer.
FDA Approves Pembrolizumab for Adults and Children With Tumor Mutational Burden–High Solid Tumors.
FDA Pipeline: Fast Track Designations in Colorectal and Pancreatic Cancers, Lymphoplasmacytic Lymphoma/Waldenström’s Macroglobulinemia.
TOFACITINIB FOR REFRACTORY IMMUNE-RELATED COLITIS.
Immune Checkpoint Inhibitor Rechallenge in Metastatic Renal Cell Carcinoma.
Safety and Efficacy of Pembrolizumab With Chemoradiotherapy in Locally Advanced Head and Neck Squamous Cell Carcinoma: A Phase IB Study.
TROPHIMMUN Trial Finds Avelumab Effective in Rare Gynecologic Tumor Resistant to Chemotherapy.
PEMBROLIZUMAB FOR LEPTOMENINGEAL CARCINOMATOSIS.
Pembrolizumab or Placebo Plus Etoposide and Platinum as First-Line Therapy for Extensive-Stage Small-Cell Lung Cancer: Randomized, Double-Blind, Phase III KEYNOTE-604 Study.
Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (LOTUS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.
Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study.
Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma.
FDA Pipeline: Two Breakthrough Therapy Designations for Fam-Trastuzumab Deruxtecan-nxki, and More.
VAXIMM Announces First Results from Phase I/II Trial in Progressive Glioblastoma with Oral T-cell Immunotherapy VXM01 in Combination with PD-L1 Inhibitor Avelumab to be Presented at ASCO20 Virtual.
Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study.
Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial.
FDA APPROVES SELPERCATINIB FOR LUNG AND THYROID CANCERS WITH RET GENE MUTATIONS OR FUSIONS.
Pazopanib for treatment of advanced malignant and dedifferentiated solitary fibrous tumour: a multicentre, single-arm, phase 2 trial.
Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial.
FDA GRANTS ACCELERATED APPROVAL TO SACITUZUMAB GOVITECAN-HZIY FOR METASTATIC TNBC.
A Phase 2 Multi-institutional Study of Nivolumab for Patients With Advanced Refractory Biliary Tract Cancer.
Nivolumab/Ipilimumab vs Nivolumab Alone in Recurrent or Persistent Ovarian Cancer.
903O – Redefining the IGCCCG classification in advanced non-seminoma.
ELEVATE-TN: Acalabrutinib With or Without Obinutuzumab vs Chlorambucil/Obinutuzumab in Patients With Previously Untreated CLL.
Tumor mutational burden is predictive of response to immune checkpoint inhibitors in MSI-high metastatic colorectal cancer.
Pembrolizumab After Completion of Locally Ablative Therapy for Oligometastatic Non-Small Cell Lung Cancer: A Phase 2 Trial.
Neoadjuvant chemotherapy plus radiation versus chemotherapy plus regional hyperthermia in high-grade soft tissue sarcomas: a retrospective comparison.
Selinexor Plus Dexamethasone Studied in Triple-Class Refractory Multiple Myeloma.
Randomised phase II trial of trofosfamide vs. doxorubicin in elderly patients with untreated metastatic soft-tissue sarcoma.
Imatinib dose reduction in major molecular response of chronic myeloid leukemia: results from the German Chronic Myeloid Leukemia-Study IV.
Aspirin Use and Risk of Cancers of the Digestive Tract.
Evaluation of EGFR inhibitor-mediated acneiform skin toxicity within the double-blind randomized EVITA trial: A thorough gender-specific analysis using the WoMo score.
Avelumab plus axitinib vs sunitinib for advanced renal cell carcinoma: Japanese subgroup analysis from JAVELIN Renal 101.
Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial.
Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma.
FDA Pipeline: Priority Reviews for Immunotherapy Based on Biomarker Status, Combination First-Line Therapy in Lung Cancer.
KTE-X19 for Relapsed or Refractory Mantle Cell Lymphoma: ZUMA-2 Trial.
FDA APPROVES NERATINIB IN COMBINATION WITH CAPECITABINE FOR METASTATIC HER2-POSITIVE BREAST CANCER.
Analysis of circulating tumour DNA (ctDNA) from patients enrolled in the IDEA-FRANCE phase III trial: Prognostic and predictive value for adjuvant treatment duration.
Analysis of Plasma Cell-Free DNA by Ultradeep Sequencing in Patients With Stages I to III Colorectal Cancer.
Circulating Tumor DNA Analyses as Markers of Recurrence Risk and Benefit of Adjuvant Therapy for Stage III Colon Cancer.
Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma.
Combination of Ruxolitinib and PEG-INF α2 Effectively Treats Patients With Polycythemia Vera, Myelofibrosis.
Lenvatinib Plus Pembrolizumab in Patients With Advanced Endometrial Cancer.
Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma.
FDA grants accelerated approval to nivolumab and ipilimumab combination for hepatocellular carcinoma.
Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer.
Neoadjuvant (Chemo)radiotherapy With Total Mesorectal Excision Only Is Not Sufficient to Prevent Lateral Local Recurrence in Enlarged Nodes: Results of the Multicenter Lateral Node Study of Patients With Low cT3/4 Rectal Cancer
Cabozantinib for Advanced Ewing Sarcoma or Osteosarcoma.
Prophylactic vaccination against human papillomaviruses to prevent cervical cancer and its precursors.
Updated Results of PURE-01 with Preliminary Activity of Neoadjuvant Pembrolizumab in Patients with Muscle-invasive Bladder Carcinoma with Variant Histologies.
SUNSHINE Trial: High-Dose Vitamin D May Benefit Patients With Metastatic Colorectal Cancer
Antibody–drug conjugate, GSK2857916, in relapsed/refractory multiple myeloma: an update on safety and efficacy from dose expansion phase I study
Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial
Mosunetuzumab Induces Complete Remissions in Poor Prognosis Non-Hodgkin Lymphoma Patients, Including Those Who Are Resistant to or Relapsing After Chimeric Antigen Receptor T-Cell (CAR-T) Therapies, and Is Active in Treatment through Multiple Lines
Analysis of 4-Year Survival With Nivolumab in Patients Previously Treated for Advanced NSCLC
ESMO 2019: PROfound: Phase 3 Study of Olaparib vs. Enzalutamide or Abiraterone for Metastatic Castration-Resistant Prostate Cancer with Homologous Recombination Repair Gene Alterations
TOPARP-B: A phase II randomized trial of the poly(ADP)-ribose polymerase (PARP) inhibitor olaparib for metastatic castration resistant prostate cancers (mCRPC) with DNA damage repair (DDR) alterations
Pharmacologic management of cognitive impairment induced by cancer therapy
Effect of Neoadjuvant Chemotherapy Plus Regional Hyperthermia on Long-term Outcomes Among Patients With Localized High-Risk Soft Tissue Sarcoma: The EORTC 62961-ESHO 95 Randomized Clinical Trial.
Sequential Versus Combination Therapy of Metastatic Colorectal Cancer Using Fluoropyrimidines, Irinotecan, and Bevacizumab: A Randomized, Controlled Study-XELAVIRI (AIO KRK0110).
Neutrophil-to-lymphocyte ratio evolution is an independent predictor of early progression of second-line nivolumab-treated patients with advanced non-small-cell lung cancers
Tumor Mutation Burden—From Doubts to Concerns—In Reply
Actively personalized vaccination trial for newly diagnosed glioblastoma
A defined commensal consortium elicits CD8 T cells and anti-cancer immunity
The fungal mycobiome promotes pancreatic oncogenesis via activation of MBL
Old drugs bring new hope to a cancer that lacks precision therapy
Hepatocytes direct the formation of a pro-metastatic niche in the liverHepatocytes direct the formation of a pro-metastatic niche in the liver
Effect of Metformin Plus Tyrosine Kinase Inhibitors Compared With Tyrosine Kinase Inhibitors Alone in Patients With Epidermal Growth Factor Receptor–Mutated Lung Adenocarcinoma
Assessment of Molecular Relapse Detection in Early-Stage Breast Cancer.
A systems mechanism for KRAS mutant allele–specific responses to targeted therapy
Neoadjuvant Pembrolizumab Combo Prolongs pCR in Phase III TNBC Study
ESMO Immuno-Oncology 2018: Does Proton Pump Inhibitor Therapy Impact the Efficacy of Nivolumab Plus Ipilimumab?
FDA Accepts Sacituzumab Govitecan Application for TNBC
FDA approves fam-trastuzumab deruxtecan-nxki for unresectable or metastatic HER2-positive breast cancer
Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer
Hair dye and chemical straightener use and breast cancer risk in a large US population of black and white women
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study
Results of a Multicenter Phase II Study of Atezolizumab and Bevacizumab for Patients With Metastatic Renal Cell Carcinoma With Variant Histology and/or Sarcomatoid Features
Nivolumab Plus Bevacizumab in Relapsed Ovarian Cancer
First Patients Dosed in Phase 1/2 Trial Testing Galinpepimut-S, Keytruda Combo in Advanced Cancers
ESMO 2019: Veliparib Plus First-Line Chemotherapy and as Maintenance Therapy in High-Grade Serous Ovarian Cancer
Safety and Efficacy of Nivolumab Monotherapy in Recurrent or Metastatic Cervical, Vaginal, or Vulvar Carcinoma: Results From the Phase I/II CheckMate 358 Trial
Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer
Regular Aspirin Use and Risk of Hepatocellular Carcinoma and Epithelial Ovarian Cancer
Do TP53 and ESR2 Interactions Change Prognosis in Triple-Negative Breast Cancer?
Metastatic triple-negative breast cancer patient with TP53 tumor mutation experienced 11 months progression-free survival on bortezomib monotherapy without adverse events after ending standard treatments with grade 3 adverse events
Ramucirumab plus pembrolizumab in patients with previously treated advanced non-small-cell lung cancer, gastro-oesophageal cancer, or urothelial carcinomas (JVDF): a multicohort, non-randomised, open-label, phase 1a/b trial
FDA Approves Pembrolizumab for the First-Line Treatment of Head and Neck Squamous Cell Carcinoma
SABCS 2018: KATHERINE Trial: Adjuvant Ado-Trastuzumab Emtansine vs Trastuzumab in Early-Stage HER2-Positive Breast Cancer
Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma
Personalized Cancer Treatment
Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial
Cancer: ‘Off-the-shelf’ stem cell treatment enters clinical trial
Vaccine Plus Trastuzumab in Preventing Recurrence of HER2–Low-Expressing Breast Cancer
Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): an updated report from a multicentre, open-label, phase 2a, multiple basket study
Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): an updated report from a multicentre, open-label, phase 2a, multiple basket study
TBCRC 022: A Phase II Trial of Neratinib and Capecitabine for Patients With Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer and Brain Metastases
Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma.
Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma
Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma.
Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma.
Lorlatinib Shows Overall and Intracranial Activity in ALK-Positive NSCLC
PACIFIC Trial of Durvalumab Sets Standard in Stage III Unresectable NSCLC
Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer
Exercise as part of cancer treatment
SABCS 2018: SOLAR-1: Liquid Biopsies in Predicting Benefit of Alpelisib in PIK3CA-Mutant Breast Cancer
ELOQUENT-3: Addition of Elotuzumab to Pomalidomide and Dexamethasone in Previously Treated Multiple Myeloma
Obesity-induced Immune Dysfunction and its Consequences in Cancer
The Mediterranean Diet Reduces the Risk and Mortality of the Prostate Cancer: A Narrative Review
Exercise Therapy for Symptom Management and Treatment in Patients With Cancer
Durvalumab Improves Overall Survival in Unresectable Stage III NSCLC
Association of Analgesic Use With Risk of Ovarian Cancer in the Nurses’ Health Studies
Nivolumab and Ipilimumab Effective against Melanoma. That Has Spread to the Brain.
The Association Between Dietary Quality and Overall and Cancer-Specific Mortality Among Cancer Survivors, NHANES III
A Menu for Cancer Risk Reduction? Five truths about the role of food and diet in cancer prevention
Abemaciclib/Pembrolizumab Combo Shows Early Promise for HR+/HER2- Breast Cancer
What is ‘checkpoint therapy’ and why did it win the medicine Nobel prize?
What is ‘checkpoint therapy’ and why did it win the medicine Nobel prize?
IMpassion130: Atezolizumab Plus Nab-Paclitaxel in Metastatic or Locally Advanced Triple-Negative Breast Cancer
Immune recognition of somatic mutations leading to complete durable regression in metastatic breast cancer.
Immune-System Therapy Eradicated Breast Cancer in New Breakthrough
Immunotherapy and radiation in glioblastoma.
Prognostic significance of marital status in breast cancer survival: A population-based study.
Timing of Aspirin and Other Nonsteroidal Anti-Inflammatory Drug Use Among Patients With Colorectal Cancer in Relation to Tumor Markers and Survival.
Cancer vaccines in colon and rectal cancer over the last decade: lessons learned and future directions.
Physician age and outcomes in elderly patients in hospital in the US: observational study
Proof-of-Principle Study of Combination Checkpoint Inhibitor Plus Trastuzumab in HER2-Positive Advanced Breast Cancer
Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers
Preventive Effects of Cocoa and Cocoa Antioxidants in Colon Cancer
American Cancer Society (ACS) Nutrition and Physical Activity Guidelines after colon cancer diagnosis and disease-free (DFS), recurrence-free (RFS), and overall survival (OS) in CALGB 89803 (Alliance)
Pembrolizumab as first-line therapy for metastatic non-small-cell lung cancer
FDA Grants DS-8201 Breakthrough Designation for HER2+ Breast Cancer
Clinical decision-making for immunotherapy in metastatic renal cell carcinoma
Osimertinib Granted Breakthrough Therapy Designation for First-Line Treatment of EGFR Mutation–Positive NSCLC
Cancers Associated With Overweight and Obesity Make Up 40% of Cancers Diagnosed in the United States
FDA Approves Daratumumab in Combination With Pomalidomide and Dexamethasone for Relapsed or Refractory Multiple Myeloma
The EGFR variant III mutant as a target for immunotherapy of glioblastoma multiforme
Efficacy and Safety of Anti-Trop-2 Antibody Drug Conjugate Sacituzumab Govitecan (IMMU-132) in Heavily Pretreated Patients With Metastatic Triple-Negative Breast Cancer
FDA Approves Panitumumab for Use in Wild-Type RAS Metastatic Colorectal Cancer
Angiosarcoma treated successfully with anti-PD-1 therapy – a case report
Genentech: Beyond The Cycle
Cancer Drug Proves to Be Effective Against Multiple Tumors
Immunotherapy Combination Shows Promise in Early Stage Triple Negative Breast Cancer
ASCO 2017: Chance of Colon Cancer Recurrence Nearly Cut in Half in Patients Who Consume Nuts
Checkpoint Inhibitors Advancing in Multiple GI Cancers
Duke researchers develop treatment that triples survival time of brain cancer patients
Long-term complete remission with Ipilimumab in metastatic castrate-resistant prostate cancer: case report of two patients
Personalized peptide vaccine-induced immune response associated with long-term survival of a metastatic cholangiocarcinoma patient
Personalized peptide vaccine-induced immune response associated with long-term survival of a metastatic cholangiocarcinoma patient
Brain Trust: Cutting-Edge Treatments for Glioblastoma on the Rise
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial
Nivolumab in renal cell carcinoma: latest evidence and clinical potential
Predictive biomarkers for the efficacy of peptide vaccine treatment: based on the results of a phase II study on advanced pancreatic cancer
Immunological Effects of Conventional Chemotherapy and Targeted Anticancer Agents
Ovarian cancer and the immune system — The role of targeted therapies
Nivolumab in patients with DNA mismatch repair deficient/microsatellite instability high metastatic colorectal cancer: Update from CheckMate 142
Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma: an international, multicentre, open-label, phase 2 trial.
Olaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma: an open-label phase 1b and randomised phase 2 trial
Systemic effect of catumaxomab in a patient with metastasized colorectal cancer: a case report
Immunotherapy moves to the front lines in fight against lung cancer
Impressive Early Data for Rovalpituzumab Tesirine in Small Cell Lung Cancer
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer
The Science Behind Guided Imagery
Complete remission in a patient with recurrent acute myeloid leukemia induced by vaccination with WT1 peptide in the absence of hematological or renal toxicity
The development and use of the E75 (HER2 369-377) peptide vaccine
Evaluation of the HER2/neu-derived peptide GP2 for use in a peptide-based breast cancer vaccine trial
Personalized peptide vaccine-induced immune response associated with long-term survival of a metastatic cholangiocarcinoma patient
Harnessing the immune system to fight cancer
Association of WT1 IgG antibody against WT1 peptide with prolonged survival in glioblastoma multiforme patients vaccinated with WT1 peptide
Neoadjuvant T-DM1/Pertuzumab Combo Boosts pCR in HER2+ Breast Cancer
Phase I clinical trial of a five-peptide cancer vaccine combined with cyclophosphamide in advanced solid tumors
Triple peptide vaccination as consolidation treatment in women affected by ovarian and breast cancer: Clinical and immunological data of a phase I/II clinical trial
Peptide vaccines in breast cancer: The immunological basis for clinical response
Triple peptide vaccination as consolidation treatment in women affected by ovarian and breast cancer: Clinical and immunological data of a phase I/II clinical trial
With Immunotherapy, Glimmers of Progress against Glioblastoma
Complete remission of liver metastasis of pancreatic cancer under vaccination with a HLA-A2 restricted peptide derived from the universal tumor antigen survivin
Short Peptide Vaccine Induces CD4+ T Helper Cells in Patients with Different Solid Cancers
Adjuvant HER2/neu peptide cancer vaccines in breast cancer
Immunological responses in a patient with glioblastoma multiforme treated with sequential courses of temozolomide and immunotherapy: Case study
Immune modulation for cancer therapy
Case report: A breast cancer patient treated with GcMAF, sonodynamic therapy and hormone therapy